Johnson & Johnson: Kidney Diseases trials

The registry lists 14 Kidney Diseases studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 4Phase 2 5Phase 3 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic NephropathyCompletedNCT02065791Phase 3Results posted
• An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney DiseaseCompletedNCT00440557Phase 3Results posted
• A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.CompletedNCT00337935Phase 2Results posted
• A Study of Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and ImplicationsCompletedNCT02830178
• An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.WithdrawnNCT02397395Phase 2
• A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance HemodialysisCompletedNCT02289703Phase 1
• An Observational Study of Case Managed Versus Non-case Managed Initiation of HemodialysisCompletedNCT01613404
• New Needle for Two-Needle HemodialysisStatus unknownNCT01416896Phase 2/3
• VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.CompletedNCT00903773Phase 1
• A Study to Evaluate the Pharmacokinetics and Safety of Levofloxacin in Patients With Varying Degrees of Renal Function.CompletedNCT00645437Phase 1
• A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney DiseaseCompletedNCT00641589Phase 1
• A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.CompletedNCT00212875Phase 2
• A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin AlfaCompletedNCT00211068
• Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.CompletedNCT00210743Phase 2